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A B S T R A C T
In primary Sjögren's syndrome (pSS), FcRL4+ B cells are present in inflamed salivary gland tissue, within or in
close proximity to ductal epithelium. FcRL4 is also expressed by nearly all pSS-related mucosa-associated
lymphoid tissue (MALT) B cell lymphomas, linking FcRL4 expression to lymphomagenesis. Whether glandular
FcRL4+ B cells are pathogenic, how these cells originate, and how they functionally differ from FcRL4- B cells in
pSS is unclear. This study aimed to investigate the phenotype and function of FcRL4+ B cells in the periphery
and parotid gland tissue of patients with pSS. First, circulating FcRL4+ B cells from 44 pSS and 54 non–SS–sicca
patients were analyzed by flow cytometry. Additionally, RNA sequencing of FcRL4+ B cells sorted from parotid
gland cell suspensions of 6 pSS patients was performed. B cells were sorted from cell suspensions as mini bulk
(5 cells/well) based on the following definitions: CD19+CD27−FcRL4- (‘naive’), CD19+CD27+FcRL4-
(‘memory’), and CD19+FcRL4+ B cells. We found that, although FcRL4+ B cells were not enriched in blood in
pSS compared with non-SS sicca patients, these cells generally exhibited a pro-inflammatory phenotype. Genes
coding for CD11c (ITGAX), T-bet (TBX21), TACI (TNFRSF13B), Src tyrosine kinases and NF-κB pathway-related
genes were, among others, significantly upregulated in glandular FcRL4+ B cells versus FcRL4- B cells. Pathway
analysis showed upregulation of B cell activation, cell cycle and metabolic pathways. Thus, FcRL4+ B cells in
pSS exhibit many characteristics of chronically activated, pro-inflammatory B cells and their gene expression
profile suggests increased risk of lymphomagenesis. We postulate that these cells contribute significantly to the
epithelial damage seen in the glandular tissue and that FcRL4+ B cells are an important treatment target in pSS.
1. Introduction
Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease
that affects about 0.04–0.1% of the general population [1,2], and pre-
dominantly woman. Salivary and lacrimal glands are the main target
tissue of the disease. Patients usually present with symptoms of dry
mouth, dry eyes, and fatigue. Mononuclear infiltration, mainly
consisting of CD4+ T cells and B cells, is a characteristic histopatho-
logical finding in pSS patients. Infiltrates are mostly concentrated
around the ductal epithelium, but lymphocytes are also present within
the epithelium where they may contribute to the formation of lym-
phoepithelial lesions (LELs) [3].
LELs are composed of proliferative metaplastic epithelial cells and
intraepithelial lymphocytes. More severe LELs harbor larger numbers of
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intraepithelial B cells [4]. The vast majority of these cells express the
inhibitory IgA-binding Fc receptor-like protein 4 (FcRL4) [5,6]. In
healthy individuals, FcRL4+ B cells are restricted to mucosal tissues
and mesenteric lymph nodes, where they participate in mucosal im-
mune responses [7]. Interestingly, FcRL4+ B cells have also been found
in the synovium of patients with rheumatoid arthritis (RA), where they
produce high levels of RANKL and thereby exhibit a pathogenic role in
this disease [8,9]. Analysis of immunoglobulin genes from FcRL4+ B
cells in RA showed high levels of somatic hypermutation in the variable
regions, which indicates that these cells are post-germinal center
memory cells. The ratio of replacement mutations in FcRL4+ B cells
indicated antigen-driven formation [8]. These studies in RA demon-
strate that FcRL4+ B cells are activated cells that may play a major role
in local immune responses in autoimmune diseases. We hypothesize
that also in pSS, glandular FcRL4+ B cells contribute to pathogenesis by
expressing pro-inflammatory factors and, as such, participate in LEL
formation.
FcRL4+ B cells may also play a role in the development of mucosa-
associated lymphoid tissue (MALT) lymphoma. This type of non-
Hodgkin lymphoma is significantly more prevalent in pSS patients
compared with population controls [10]. The neoplastic B cells of
parotid MALT lymphomas are located in and around LELs, and widely
express FcRL4 [5,11]. Notably, MALT lymphomas in pSS develop pre-
ferentially in the parotid glands, in which FcRL4+ B cells are more
abundant compared to labial salivary glands [5].
Whether glandular FcRL4+ B cells are activated at extraglandular
(mucosal) sites and subsequently migrate to the inflamed salivary
glands of pSS patients, or whether they are formed locally in these
glands is not known. We hypothesized that in a scenario of extra-
glandular formation and migration, the frequency of circulating
FcRL4+ B cells would differ between pSS patients and non-SS sicca
patients. To address this, we studied the frequency and phenotype of
FcRL4+ B cells in the periphery using flow cytometry. To investigate
how glandular FcRL4+ B cells contribute to pathogenesis, we sorted
these cells from parotid glands of pSS patients and compared their gene
expression profile with FcRL4- B cells using mini-bulk RNA sequencing.
Changes in gene expression between FcRL4+ and FcRL4- B cells were
used in pathway analyses to determine what, if any role, FcRL4+ B cells
have in inflammation, LEL formation, and lymphomagenesis. We found
that circulating FcRL4+ B cells have a pro-inflammatory phenotype, but
frequencies were similar in pSS patients and non-SS sicca controls.
Glandular FcRL4+ B cells had higher expression levels of genes in-
volved in cell trafficking, B cell activation, and the NF-kappa B (NF-κB)
pathway, linking these cells to LEL formation and, possibly, predis-
position to lymphomagenesis.
2. Patients and methods
2.1. Immunophenotyping of circulating FcRL4+ B cells
Consecutive patients, referred to the University Medical Center
Groningen (UMCG) for suspicion of SS were included in an inception
cohort (n = 98). Informed consent was obtained according to the
Declaration of Helsinki and the study was approved by the Medical
Research Ethics Committee of the UMCG (METc2013.066). Inclusion
criteria were age ≥18 years and sicca complaints. Patients who fulfilled
2016 ACR-EULAR criteria for SS were classified as pSS patients. Non-SS
sicca patients were patients who did not fulfill 2016 ACR-EULAR cri-
teria for SS. Patients diagnosed with other autoimmune diseases, he-
patitis C, and HIV patients were excluded. From the 98 patients in-
cluded in our cohort, 44 patients were classified as pSS and 54 as non-
SS sicca patients. Of the 44 pSS patients, 80% were naive for treatment
with corticosteroids or disease-modifying anti-rheumatic drugs. Two
pSS patients were diagnosed with MALT lymphoma. Cryopreserved
peripheral blood mononuclear cells were thawed and the frequency and
phenotype of FcRL4+ B-cells were assessed by flow cytometry. The
antibodies used are listed in Supplementary Table 1. Fixable viability
dye eF506 (eBioscience) was used for live/dead discrimination. Data
were acquired on a FACS-LSRII flow cytometer (Becton Dickinson, USA)
and analyzed using FlowJo software (Tree Star, USA).
2.2. Tissue samples for RNA sequencing
FcRL4+ B cells are present in inflamed salivary gland tissue of pa-
tients with pSS, particularly in parotid gland tissue, but these cells are
almost absent from salivary gland tissue of non-SS sicca patients and
healthy individuals [5]. To investigate the phenotype and function of
glandular FcRL4+ B cells in pSS patients, fresh parotid gland tissue was
obtained from 6 adult patients who underwent a diagnostic biopsy.
Patients were selected based on anti-SSA/Ro positivity and a high
clinical suspicion of pSS. All patients fulfilled 2016 ACR-EULAR criteria
for pSS. Surgeries were performed at the department of Oral and
Maxillofacial Surgery of the UMCG. Permission to collect these tissues
for research purposes was obtained from the Medical Research Ethics
Committee of the UMCG (METc2016.010). Cell suspensions were pre-
pared as described by Pringle et al. [12], with the following adaptions:
biopsies were manually cut using scissors, the incubation period for
enzyme-based digestion was 30 min and 32.5 μL digestion buffer was
used per milligram of tissue.
2.3. Fluorescence-activated cell sorting for RNA sequencing
Fresh parotid gland cell suspensions were incubated with antibodies
(identified below) for 30 min at 4 °C and washed twice in PBS/0.5%
BSA/2 mM EDTA. The following antibodies were used: anti-human-
CD19-eF450 (clone HIB19), anti-human-CD27-APC (clone O323), both
from eBioscience, and anti-human-FcRL4-PE (clone 413D12,
Biolegend). Immediately before sorting, cells were stained with propi-
dium iodide (eBioscience) for live/dead discrimination. Gating was
performed as described in Supplementary Fig. 1. Cells were sorted as
5 cells/well into 96-wells PCR plates containing 2 μl of lysis buffer
(0.2% Triton X-100 (Sigma-Aldrich) + 2 U/μL RNAse inhibitor
(Westburg-Clontech)), 1 μl of 10 μM oligo-dT30VN primer (Biolegio)
and 1 μl of 4 × 10 mM dNTP mix (Westburg-Fermentas) per well. Cells
were sorted on a MoFlo Astrios cell sorter (Beckman Coulter).
2.4. Preparation of cDNA libraries and sequencing
Complementary DNA (cDNA) library preparation was based on the
Smart-seq2 protocol by Picelli et al. [13], but the following protocol
adaptions were made to enable 3′-paired-end sequencing to decode cell
barcodes and unique molecular identifiers (UMIs) from read 1: After a
3-min incubation–ligation step at 72 °C, a template switching oligo
primer containing UMIs was bound to the poly-A tail of RNA tran-
scripts, after which these were reverse transcribed using a reverse
transcriptase (RT) mastermix (2.5 U SmartScribe RT, 0.25 U RNAse
inhibitor (both from Westburg-Clontech), 1x SmartScribe first-strand
buffer, 2 nM dithiothreitol (both from LifeTechnologies), 1 M betaine
(BioUltra ≥99.0%; Sigma-Aldrich), 1 μM barcode-template switching
oligo (BC-TSO; Biolegio)). After RT, an exonuclease step was added to
remove unbound oligo-dT primers. One μL of exonuclease I (1:400 di-
lution in pure water) was added to each well and the plate was in-
cubated 45 min at 37 °C, to activate the enzyme, immediately followed
by 15 min at 85 °C to inactivate the enzyme. Pre-amplification of cDNA
was performed using the KAPA HiFi HotStart ReadyMix (KAPA Bio-
systems) and BC-specific primers (fit at the end of the adapters). Sam-
ples were purified using Agencourt Ampure XP Beads (Beckman
Coulter). The presence and size distribution of the obtained PCR pro-
duct was measured on a PerkinElmer LabChip GX high-sensitivity DNA
chip. Next, equimolar pooling of PCR products was performed. To tag
the DNA with adapter sequences, a tagmentation step was incorporated
using the Illumina Nextera XT DNA sample preparation kit, according
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to the manufacturer's protocol, with 500 pg of pooled cDNA. Subse-
quently, the subpools were indexed using a N7xx primer from the
Nextera XT DNA sample preparation kit and a custom P5-TSO hybrid
primer (10 μM) with the Nextera PCR mastermix. The concentration
and size distribution of the obtained Nextera products were measured
on a PerkinElmer LabChip GX high-sensitivity DNA chip and a super-
pool was prepared by equimolar pooling of the six Nextera products.
The superpool was divided over four lanes and sequenced on an Illu-
mina NextSeq 500 instrument. The first read consisted of 17 bp, to
sequence the cell-barcode (10 bp) and UMI (7 bp), followed by the
index read sequencing the Nextera index (8 bp). The second read
consisted of a 50 bp fragment, sequencing the last part of the captured
gene. For mini-bulk samples, the median sequencing depth was 2.1*106
reads per sample.
2.5. Read alignment, quality control and gene expression estimation
Dropseq tools 1.12 was used to extract well barcodes and UMIs from
the reads [14]. The extracted well and UMI reads were flagged with
bam tags and then stored in bam format together with the corre-
sponding read. For quality control, only reads with a well and UMI
barcode with a minimum basecallQuality of 10 were included. Of the
remaining reads, the Smart adapter and PolyA tails were removed using
Dropseq. In the next step, reads were aligned to the human genome
(hg19) using STAR v2.5.1b with default settings [15]. The aligned reads
were filtered for uniquely mapping reads. Before gene quantification,
aligned reads were sorted using Picard tools 2.2.2 (https://
broadinstitute.github.io/picard). Ensembl version 75 was used to map
protein-coding transcripts. Quantification of gene expression was per-
formed using Dropseq filtering on unique UMIs.
2.6. RNA expression data analysis
All statistical analysis and plotting of RNA-seq data was performed
using R software v3.6.1 [16]. UMI-corrected read counts were used as
input, correcting for PCR duplicates [17]. Immunoglobulin variable
region gene transcripts were removed, because these sequences are not
adjacent to the 3′ end and therefore, variance in amplification of the
entire variable region is expected between samples with the current
method. For differential expression analysis of mini-bulk samples,
DESeq2 v1.24.0 was used [18], following the recommendations for
single-cell data, because of the high amount of zero's in the dataset. Six
(biological) replicates per cell subset per patient were included in the
analysis. Genes with ≤1 read across all samples were first removed
from the dataset. The DESeq2 model included the cell type (condition)
and patient number (batch). Approximate posterior estimation for
generalized linear model (apeglm) was used to estimate the logarithmic
fold change [19]. Differentially expressed genes were analyzed for
pathway enrichment using Ingenuity Pathway analysis (QIAGEN Inc.,
USA) [20].
2.7. Immunohistochemistry
Formalin-fixed (4%), paraffin-embedded parotid gland tissue sec-
tions (4 μm) of five pSS patients from the inception cohort were in-
cluded. Patients were selected based on the presence of LELs (identified
by H&E staining). After deparaffinization and heat-induced antigen
retrieval in sodium citrate buffer (pH 6.0) for 20 min and endogenous
peroxidase (0.3% H2O2) blocking, Ultra V Block (ThermoFisher
Scientific) was applied for 5 min. Slides were incubated overnight at
4 °C with 2.5 μg/mL monoclonal mouse anti-human PAX5 antibody (BD
Biosciences, clone 24/Pax-5) and 1 μg/mL monoclonal rabbit anti-
human CD11c antibody (Abcam, clone EP1347Y) diluted in PBS/1%
BSA/0.05% Tween-20. Secondary antibody-based detection was per-
formed using the MultiVision polymer detection system (anti-rabbit/
HRP and anti-mouse/AP polymers; ThermoFisher Scientific) according
to the manufacturer's instructions.
2.8. Statistical analysis
The Mann-Whitney U test was used to compare frequencies and
numbers of FcRL4+ B cells in blood between pSS patients and non-SS
sicca patients. P-values< 0.05 were considered statistically significant.
For statistical analysis of mini-bulk RNA sequencing, we used DESeq2
software with a likelihood ratio test design [18]. P-values for differ-
entially expressed genes were adjusted by the Benjamini-Hochberg
method and are hereafter indicated as false detection rate (FDR).
3. Results
3.1. Immunophenotyping of circulating FcRL4+ B cells in pSS and non-SS
sicca patients
First, we compared frequencies of circulating FcRL4+ B cells be-
tween pSS and non-SS sicca patients. Patient characteristics are sum-
marized in Table 1. We measured co-expression of multiple surface
markers expressed by B cells, including CD27, CD21, and CXCR3
(Fig. 1A). We found no significant differences in frequencies of circu-
lating FcRL4+ B cells between pSS and non-SS sicca patients (Fig. 1B).
Also, absolute numbers of these cell subsets were not significantly al-
tered (data not shown). Two pSS patients with MALT lymphoma did not
show aberrant frequencies of these cells either. Circulating FcRL4+ B
cells comprised both CD27− and CD27+ cells. A large proportion of
circulating FcRL4+ B cells expressed low levels of CD21 and co-ex-
pressed CXCR3 (Fig. 1B). We did not observe significant phenotypical
differences in circulating FcRL4+ B cells between pSS and non-SS sicca
patients. Their low prevalence notwithstanding, CXCR3 expression of
circulating FcRL4+ B cells suggests that these cells do have the capacity
to migrate to inflamed tissue sites.
3.2. RNA sequencing of B cells isolated from parotid glands of pSS patients
Also in the inflamed salivary gland tissue of patients with pSS, the
number of FcRL4+ B cells is relatively low, albeit higher in parotid
compared to labial glands [5]. Here, FcRL4+ B cells concentrate around
the ductal epithelium [5]. In contrast to pSS, B cells are nearly absent
around and within the striated ducts in salivary gland tissue of non-SS
sicca patients [4]. To begin exploring the potential role of FcRL4+ B
cells, we sorted these cells, as well as FcRL4- B cell subsets, from parotid
gland tissue of six patients with pSS and then performed RNA sequen-
cing. Gene expression profiles were compared between FcRL4+,
Table 1
Baseline characteristics of the inception cohort used for immunophenotyping of
FcRL4+ B cells in blood.
Characteristic pSS (n = 44) non-SS sicca (n = 54)
Age, median (IQR), years 54 (45–62) 48 (40–56)
Female gender, n (%) 42 (96) 46 (85)
Xerostomia, n (%) 42 (96) 52 (96)
Keratoconjunctivitis sicca, n (%) 39 (89) 52 (96)
UWSF ≤ 0.1 mL/min, n (%) 23 (52) 22 (41)
Schirmer's test ≤ 5mm/5 min, n (%) 36 (82) 31 (57)
OSS ≥ 5, n (%) 19 (43) 6 (11)
Parotid gland enlargement, n (%) 18 (41) 8 (15)
ESSDAI, median (IQR) 4 (1–9) –
IgG (g/L), median (IQR) 16 (12–20) 10 (8–12)
Anti-Ro/SSA positive, n (%) 33 (75) 3 (6)
Anti-La/SSB positive, n (%) 18 (41) 0 (0)
RF positive, n (%) 26 (59) 1 (2)
IQR: Interquartile range; UWSF: Unstimulated whole salivary flow; OSS: Ocular
Staining Score; ESSDAI: EULAR Sjögren's Syndrome Disease Activity Index; RF:
Rheumatoid factor.
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FcRL4−CD27− ‘naive’ and FcRL4−CD27+ ‘memory’ B cells. One pa-
tient sample (out of six) was excluded because of low RNA yields during
library preparation. Of the remaining five patients, one was diagnosed
with MALT lymphoma. Data from this patient were excluded from
differential expression analysis, because the transcriptional profile of
these cells may bias the analysis of non-lymphoma B cells. Character-
istics of the patients included (n = 4) are shown in Table 2. Data from
mini-bulk samples (5 cells per subset per patient, 6 replicates per
subset) from four patients were used to compare the gene expression
profiles between B cell subsets. Principal component (PC) analysis did
not show very distinct clustering of the sorted subsets, although
FcRL4+ cells from three patients clustered separately in PC2 (Fig. 2A).
By using DESeq2 software to compare FcRL4+ B cells with
FcRL4−CD27− ‘naive’ B cells and FcRL4−CD27+ ‘memory’ B cells, we
identified 526 differentially expressed genes in FcRL4+ B cells (DEG;
FDR<0.05).
Next, we evaluated differentially expressed genes with a focus on
genes with known immune function (Fig. 2B). We found differential
expression of several genes previously associated with FcRL4+ B cells
[8,21,22]. These genes included ITGAX (CD11c), TBX21 (T-bet),
CXCR5, CD40 and the Src tyrosine kinases FGR, LYN, and LCK. Al-
though CXCR3 was not marked as a DEG, we did observe upregulation
of CXCR3 in FcRL4+ B cells (Fig. 2B). At the same time, expression of
lymphoid tissue homing factors SELL (CD62L) and CCR7 was reduced
(Supplementary Table 2). Upregulation of CD11c and CXCR3, and si-
multaneous downregulation of CXCR5, CD62L, and CCR7 are important
for cell trafficking into inflamed tissues. We also found upregulation of
genes associated with activation of both the canonical and non-cano-
nical NF-κB signaling pathway: TNFRSF13B (TACI), NFKB1 (p50), and
MAP3K14 (NIK). Expression levels of NFKBIA (IκBα) and NFKBID
(IκBNS), negative regulators of NF-κB, were significantly down-
regulated in FcRL4+ B cells. Although we did not detect many
Fig. 1. FcRL4+ B cells in peripheral blood of pSS patients and non-SS sicca patients. (A) Gating strategy used to identify FcRL4+ B cells in peripheral blood.
Lymphocytes were gated from single, live cells using forward and side scatter properties and fixable viability dye staining. (B) Frequencies of FcRL4+ cells within the
B-cell compartment and frequencies of CD21loCXCR3+ cells within the FcRL4+ B-cell compartment are shown. Data from pSS patients (n = 44) and non-SS sicca
patients (n = 54) were included. P-value< 0.05 was considered significant. Mann-Whitney U test was used for statistical analysis. Ns = not significant.
Table 2
Demographic, clinical and histologic characteristics of patients included for parotid gland B cell RNA sequencing.




















Patient 1 74 F 8 Yes No No 8.8 NAb NAb + – +
Patient 2 69 F 25 Yes Yes No 39 4 1.1 – – +
Patient 3 61 F 20 Yes Yes Yes 11 4 3.2 + – +
Patient 4 68 F 27 Yes Yes Yes 33 4 1.2 + – +
RF: Rheumatoid factor; LEL: Lympho-epithelial lesion; GC: Germinal center; NA: Not assessed.
a > 30% IgG-containing plasma cells over< 70% IgA-containing plasma cell in diagnostic biopsy.
b Chisholm and focus score could not be calculated because of atrophy and a limited area of parenchyma in the diagnostic biopsy. In the parenchyma that was left,
we were able to identify, however, LELs and a plasma cell shift towards IgG. These two findings are indicative of pSS.
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Fig. 2. Differential gene expression in FcRL4+ B cells. Clustering and differential gene expression for mini-bulk samples were analyzed using DESeq2 software.
(A) Principal Component Analysis (PCA) plot of all included samples, colored by (flow cytometry-based) cell subset. (B) Violin plots showing normalized transcript
counts (y-axis) per cell type (x-axis) for genes with known immune function that were differentially expressed in FcRL4+ B cells, compared with both FcRL4- subsets
(FDR<0.05). Each black dot represents a 5-cell sample. * Not marked as differentially expressed gene in statistical analysis.
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transcripts coding for cytokines, IL6 was significantly upregulated.
Genes that are involved in regulation of B cell differentiation, i.e.MZB1,
IL4R, and BACH2, were expressed at lower levels in FcRL4+ B cells
(Fig. 2B). Other possibly relevant genes upregulated in these cells were
CCR5, CD97 and ITGA4 (cell trafficking) as well as IFNGR1 and IL27RA
(interferon type II-mediated response). A full list of differentially ex-
pressed genes with FDR<0.1 is included as Supplementary Table 2.
3.3. Pathway analysis of differentially expressed genes
Using Ingenuity Pathway Analysis (IPA), we found many differen-
tially regulated canonical pathways in FcRL4+ B cells, compared with
FcRL4- ‘memory’ B cells (Supplementary Table 3). Pathways involved in
B cell activation, metabolic and cell cycle-related pathways were par-
ticularly enriched in FcRL4+ B cells (Fig. 3A). In addition to IPA, we
could identify specific patterns of gene expression associated with
CD11c+ B cells [23], B cell differentiation, and tumor suppression in
FcRL4+ B cells (Fig. 3B).
3.4. Presence of CD11c+ B cells in parotid gland tissue
Since ITGAX (CD11c) was significantly upregulated in FcRL4+ B
cells, compared with FcRL4- B cells, we aimed to confirm the presence
of CD11c+ B cells in inflamed parotid gland tissue from pSS patients
with LELs. Because CD11c is also expressed by dendritic cells, CD11c+
B cells were characterized by co-expression of CD11c and the B-cell
lineage-specific transcription factor Pax5. CD11c+ B cells were indeed
present in periductal infiltrates of pSS patients (Fig. 4A). However,
within the ductal epithelium, only a fraction of B cells showed positivity
for CD11c (Fig. 4B), while FcRL4 was shown to be expressed by the vast
majority of these cells [5].
4. Discussion
FcRL4 is expressed by epithelium-associated B cells in the salivary
glands of pSS patients [5]. However, the origin, phenotype and function
of FcRL4+ B cells in pSS remain poorly understood. In addition to
immunophenotyping of circulating FcRL4+ B cells, we investigated, for
the first time, the gene expression profile of glandular FcRL4+ B cells
that were isolated from parotid gland tissue of pSS patients. Glandular
FcRL4+ B cells showed upregulation of multiple genes involved in B
cell trafficking and B cell activation. Our results indicate that FcRL4+ B
cells in pSS exhibit many characteristics of chronically activated, pro-
inflammatory, CD11c+T-bet+ B cells, which were recently shown to be
involved in the pathogenesis of systemic lupus erythematosus [24,25].
We postulate that FcRL4+ B cells contribute significantly to the epi-
thelial damage seen in the glandular tissue of pSS patients.
Glandular FcRL4+ B cells were studied using mini-bulk RNA se-
quencing. We used cell sorting to enrich for FcRL4+ and FcRL4-
glandular B cells. This approach allowed us to partially overcome the
limited number of cells and fresh biopsy samples available. Gene ex-
pression analysis of the mini-bulk samples showed upregulation of
CXCR3 almost exclusively in FcRL4+ B cells, together with down-
regulation of CXCR5. Similarly, flow cytometric analysis of circulating
B cells showed that a large proportion of FcRL4+ B cells in blood co-
expresses CXCR3. This may explain inflammation-induced homing to
the ductal epithelial cells of the affected salivary glands, which secrete
high levels of the chemokine CXCL10/IP-10 [26], the ligand for CXCR3.
Additionally, integrins (e.g., ITGAX (CD11c)) and other adhesion mo-
lecules (e.g., CD97) were upregulated in FcRL4+ B cells, compared with
FcRL4- B cells. The expression of CD11c by B cells in periductal in-
filtrates and LELs within parotid gland tissue of pSS patients was con-
firmed by immunohistochemistry, albeit that CD11c was not expressed
by all intraepithelial B cells. Since CD11c is considered to be a marker
of recent activation [25,27], our results suggest that FcRL4+ B cells
have been activated at the epithelial border. Subsequently, the ex-
pression of CD11c and other adhesion molecules by these cells may
result in retention of these cells around and within the epithelium by
interaction with their ligands, such as VCAM-1 and ICAM-1. FcRL4+ B
cells further exhibited increased transcript expression of Src family ki-
nases (HCK, FGR, LYN), which are important for integrin signal trans-
duction [28]. The phenotype of glandular FcRL4+ B cells is thus con-
sistent with results from earlier studies that analyzed the transcription
profile of FcRL4+ B cells in tonsils, the blood of HIV-viremic individuals
Fig. 3. Pathway analysis in FcRL4+ B cells. (A) Pathway enrichment was assessed using Ingenuity Pathway Analysis (IPA). A list of differentially expressed genes
(DEG) between FcRL4+ B cells and FcRL4−CD27+ ‘memory’ B cells, with an FDR<0.1, was used as input. Pathways related to B cell activation and cell cycle were,
amongst others, significantly enriched in FcRL4+ B cells. Z-scores are a measure of the match between expected relationship direction and observed gene expression.
(B) Specific patterns of gene expression in FcRL4+ B cells are presented. Colors indicate shrunken log 2 fold change values of DEG genes with FDR<0.05. (For
interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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or synovia of patients with RA [8,21,22].
Previous studies have shown that enhanced expression of CD11c by
memory B cells is associated with multiple autoimmune conditions and
chronic immune stimulation [23]. CD11c+ memory cells are atypical
memory cells, characterized by low expression of CD27 and low ex-
pression of CD21. These cells exhibit autoreactive specificities, are re-
fractory to BCR stimulation, and respond robustly to TLR activation
[23]. A similar pattern of downregulated BCR signaling and enhanced
TLR signaling has been shown for FcRL4+ B cells [29]. There is some
evidence that binding of IgA to FcRL4 on the B cells is important for this
switch from adaptive to innate signaling [29]. Negative regulation of
BCR-induced signaling may be established by upregulation of LYN, as
we observed in glandular FcRL4+ B cells. Lyn is a Src tyrosine kinase
that can initiate, but mostly negatively regulates BCR signaling [30].
The transcriptional profile of FcRL4+ B cells from parotid glands fur-
ther indicates that these cells have indeed been activated, as upregu-
lation of multiple genes involved in NF-κB signaling was seen. One of
these genes was TNFRSF13B, coding for TACI, a receptor that binds
both BAFF and APRIL. Upon binding, NF-κB signaling and B cell sur-
vival are induced [31]. BAFF and APRIL are significantly upregulated in
the salivary glands of pSS patients and are also produced by the ductal
epithelial cells [32]. Thus, binding of BAFF and/or APRIL to TACI ex-
pressed by FcRL4+ B cells may promote their activation and survival.
Unexpectedly, the upregulation of NF-κB pathway genes in glandular
FcRL4+ B cells was not accompanied by increased expression levels of
genes encoding for pro-inflammatory cytokines, except for IL6, which
was significantly upregulated in some FcRL4+ B cells. Low abundance
of cytokine transcript detection is a known issue in (single-cell) RNA
sequencing and may be due to short half-life of cytokine mRNAs. Thus,
additional effector functions of FcRL4+ B cells that may contribute to
epithelial damage and formation of LELs need further investigation.
In contrast to findings regarding CD11c+T-bet+ B cells in SLE, we
did not find evidence that FcRL4+ B cells are differentiating into an-
tibody-secreting cells (ASC), as the required transcription factors (e.g.
IRF4, PRDM1, XBP1 [33]) were either downregulated or not detected.
This is in line with our previous histologic observation that FcRL4+ B
cells lack IRF4 and Blimp-1 protein expression [5]. MZB1, which is
important for differentiation of marginal zone B cells into ASC [34],
was also downregulated. Oppositely, the expression of BACH2, which is
a negative regulator of effector B cell differentiation and highly ex-
pressed by naïve B cells, was reduced in FcRL4+ B cells, similar to what
has been observed in ASC [35]. Together our results suggest that, de-
spite their activated state, the expression of FcRL4+ puts a brake on
ASC formation.
FcRL4 is not only expressed by epithelium-associated B cells, but
also by MALT lymphomas [11]. The clear co-localization of neoplastic B
cells with epithelial cells in MALT lymphomas suggests that this disease
depends on the interaction between B cells and epithelial cells. We
therefore speculate that the highly proliferative, activated FcRL4+ B
cells may become neoplastic B cells [5]. In support of this notion, we
observed upregulation of several genes in FcRL4+ B cells that are as-
sociated with lymphomagenesis. Firstly, expression levels of several NF-
κB pathway genes are increased in FcRL4+ B cells as well as in MALT
lymphoma and the vast majority of MALT lymphoma-associated gene
translocations is associated with NF-κB activation [36]. In pSS, a
germline missense polymorphism in TNFAIP3, a gene coding for an
important negative feedback regulator of the NF-κB pathway, is asso-
ciated with lymphoma development, particularly in patients with early
disease onset [37,38]. Also, NF-κB2 was upregulated in B cells from SS
patients with lymphoma who harbored a missense mutation in the
TNFRSF13C (BAFF-R) gene [39]. These findings underline that im-
paired control of NF-κB activation increases the risk of lymphoma. An
additional factor that may contribute to lymphomagenesis is upregu-
lation of genes that promote cell survival, such as TNFRSF13B [40], and
downregulation of pro-apoptotic and tumor suppressor genes (SMAD3
[41], RGS16 [42,43]) in FcRL4+ B cells, probably saving them from
apoptosis. Finally, we found upregulation of IL27RA, which is specifi-
cally overexpressed in MALT lymphoma compared with other B-cell
lymphomas [44]. In mice, IL-27 signals directly to B cells and promotes
differentiation towards germinal center (GC) B cells via STAT1 [45]. IL-
27R was expressed on GC B cells following CD40 stimulation, inducing
STAT1 phosphorylation in humans [46]. IL-27 is also able to induce T-
bet expression in naive and memory B cells [46,47].
In addition to increased activity of the IL-27R/STAT1/T-bet axis in
FcRL4+ B cells, observed in the current study, others have shown that
expression levels of IFN-γ and type-II IFN inducible genes were in-
creased in minor salivary gland tissue of SS patients with versus without
lymphoma [48]. These data suggest that a broad type 1 immune re-
sponse, coordinated by T-bet expression in different cell types, is as-
sociated with lymphomagenesis in pSS patients. A possible explanation
for this association is that T-bet in B cells controls expression of acti-
vation-induced cytidine (AID) [49], which is essential for somatic hy-
permutation and isotype switching in B cells. A previous study showed
that FcRL4+ memory B cells have higher expression levels of AICDA
(coding for AID) than FcRL4- memory B cells [21]. Importantly, AID can
also target many other genes outside immunoglobulin loci, which may
result in off-target, potentially oncogenic, mutations [50]. Although
AICDA was not a differentially expressed gene in our dataset, low
transcript counts of this gene were found in some FcRL4+ samples. We
hypothesize that extra-follicular expression of AICDA in FcRL4+ B cells
may contribute to transformation of these cells towards neoplastic
MALT lymphoma cells.
A limitation of our study is the small number of patient samples,
which was due to the low frequency of available fresh parotid gland
biopsies from patients that fulfilled our inclusion criteria (high suspi-
cion of pSS and anti-SSA positivity). Another limitation could be that
the average age of the patients included is relatively high (68 years).
We did not select patients by age nor by histopathological
Fig. 4. Presence of CD11c+ B cells in
parotid gland tissue of pSS patients.
Double staining for CD11c (brown) and the
B-cell lineage-specific transcription factor
Pax5 (blue) in two pSS patients with lym-
phoepithelial lesions (LELs) (A–B). Large
numbers of B cells are present within LELs
and around the inflamed ducts. Single
CD11c+ positive cells indicate dendritic
cells. Examples of CD11c+Pax5+ cells are
indicated by yellow arrows. (For inter-
pretation of the references to color in this
figure legend, the reader is referred to the
Web version of this article.)
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characteristics. Nonetheless, to our best knowledge this is the first study
to reveal the gene expression profile of FcRL4+ B cells isolated from
salivary gland tissue of pSS patients. FcRL4+ B cells show similarities in
gene expression profile to chronically activated CD11c+T-bet+
memory B cells in systemic lupus erythematosus patients [24], as well
as strong NF-κB activation. Specific chemokine receptor and integrin
expression may be responsible for guidance to and cross-talk with
epithelial cells that form LELs. By interacting with epithelial cells and
secreting IL-6, FcRL4+ B cells may contribute to pSS histopathology
and hyposalivation. Lastly, we show that FcRL4+ B cells isolated from
glandular tissue of pSS patients express anti-apoptotic factors that,
combined with a high proliferative capacity and possibly somatic hy-
permutation, may put them at risk of lymphomagenesis. Thus, B-cell
targeting therapies, such as rituximab, that deplete FcRL4+ B cells and
restore of the ductal epithelium may be beneficial in patients with pSS
and even prevent MALT lymphoma development within the salivary
glands.
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